免疫调节 TGF-β 信号在肝细胞癌中的作用。

Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.

机构信息

Department of Gastroenterology, Hepatology, & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Women's Health Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

出版信息

Trends Mol Med. 2019 Nov;25(11):1010-1023. doi: 10.1016/j.molmed.2019.06.007. Epub 2019 Jul 25.

DOI:10.1016/j.molmed.2019.06.007

PMID:31353124

Abstract

Hepatocellular carcinoma (HCC) is an inflammation-induced and chemotherapy-resistant cancer. Dysregulated signaling in the transforming growth factor beta (TGF-β) pathway plays a central role in inflammation, fibrogenesis, and immunomodulation in the HCC microenvironment. This review dissects the genetic landscape of the TGF-β superfamily genes in HCC and discusses the essential effects of this pathway on the tumor immune microenvironment. We highlight the TGF-β signature as a potential biomarker for identifying individualized immunotherapeutic approaches in HCC. An improved understanding of the detailed mechanisms of liver cancer immunogenicity and the specific role of TGF-β in mediating immunotherapy resistance in HCC will provide important insights into HCC immune escape and promote the development of biomarker-derived combination immunotherapies for HCC.

摘要

肝细胞癌（HCC）是一种炎症诱导且对化疗有抗性的癌症。转化生长因子-β（TGF-β）通路中的信号失调在 HCC 微环境中的炎症、纤维化和免疫调节中起着核心作用。这篇综述剖析了 HCC 中 TGF-β 超家族基因的遗传图谱，并讨论了该通路对肿瘤免疫微环境的重要影响。我们强调 TGF-β 特征作为识别 HCC 个体化免疫治疗方法的潜在生物标志物。对肝癌免疫原性的详细机制以及 TGF-β在介导 HCC 免疫治疗耐药中的具体作用的深入理解，将为 HCC 免疫逃逸提供重要的见解，并促进基于生物标志物的 HCC 组合免疫疗法的发展。